|
EP3564379A1
(en)
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP3215191B1
(en)
|
2014-11-05 |
2024-08-14 |
Voyager Therapeutics, Inc. |
Aadc polynucleotides for the treatment of parkinson's disease
|
|
CN114717264A
(zh)
|
2014-11-14 |
2022-07-08 |
沃雅戈治疗公司 |
治疗肌萎缩性侧索硬化(als)的组合物和方法
|
|
KR20230145206A
(ko)
|
2014-11-14 |
2023-10-17 |
보이저 테라퓨틱스, 인크. |
조절성 폴리뉴클레오티드
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
JP6754361B2
(ja)
*
|
2014-12-16 |
2020-09-09 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ |
若年型バッテン病のための遺伝子療法
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
AU2016366549B2
(en)
|
2015-12-11 |
2022-11-10 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (AAVs)
|
|
EP3448987A4
(en)
|
2016-04-29 |
2020-05-27 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
US10584337B2
(en)
|
2016-05-18 |
2020-03-10 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
IL297576B2
(en)
|
2016-05-18 |
2024-02-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
EP3831281B1
(en)
|
2016-08-30 |
2026-02-25 |
The Regents of The University of California |
Devices and systems for biomedical targeting and delivery
|
|
FI3574091T3
(fi)
|
2017-01-30 |
2023-05-03 |
Brainvectis |
Ekspressiovektori kolesterolin 24-hydrolaasia varten polyglutamiinin toiston spinoserebellaariataksioiden hoidossa
|
|
CA3059891A1
(en)
|
2017-04-14 |
2018-10-18 |
National Taiwan University |
Gene therapy for aadc deficiency
|
|
MX2019013172A
(es)
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
EP3618839A4
(en)
|
2017-05-05 |
2021-06-09 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
CA3070087A1
(en)
|
2017-07-17 |
2019-01-24 |
Voyager Therapeutics, Inc. |
Trajectory array guide system
|
|
US11512327B2
(en)
*
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
JP2020533968A
(ja)
*
|
2017-08-25 |
2020-11-26 |
オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． |
組換えアデノ随伴ベクター
|
|
MX2020003042A
(es)
*
|
2017-09-29 |
2020-11-18 |
Voyager Therapeutics Inc |
Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
|
|
AU2018350700B2
(en)
*
|
2017-10-16 |
2025-04-24 |
VeonGen Therapeutics GmbH |
AAV vectors
|
|
TW202413649A
(zh)
|
2017-10-16 |
2024-04-01 |
美商航海家醫療公司 |
肌萎縮性脊髓側索硬化症(als)之治療
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
US11376337B2
(en)
|
2017-11-02 |
2022-07-05 |
California Institute Of Technology |
Expression of neuropeptides
|
|
US11458129B2
(en)
|
2017-11-02 |
2022-10-04 |
California Institute Of Technology |
Neurokinin antagonists and uses thereof
|
|
US20190202866A1
(en)
*
|
2017-12-22 |
2019-07-04 |
William Marsh Rice University |
Viral nanoparticles and methods of use thereof
|
|
JP7430652B2
(ja)
|
2018-03-05 |
2024-02-13 |
ザ チルドレンズ メディカル センター コーポレーション |
蝸牛および前庭細胞に核酸を送達するための組成物および方法
|
|
EP3774853A1
(en)
*
|
2018-03-30 |
2021-02-17 |
The Board of Trustees of the Leland Stanford Junior University |
Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism
|
|
CA3095179A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
MX2020010465A
(es)
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus para direccionamiento a tejidos oftalmicos.
|
|
BR112020020266A2
(pt)
|
2018-04-03 |
2021-01-19 |
Stridebio, Inc. |
Vetores de vírus com evasão de anticorpos
|
|
EP3781174A4
(en)
|
2018-04-09 |
2022-01-26 |
Allen Institute |
RESCUE OF VOLTAGE CONTROLLED SODIUM CHANNEL FUNCTION IN INHIBITORY NEURONS
|
|
WO2019200016A1
(en)
|
2018-04-10 |
2019-10-17 |
President And Fellows Of Harvard College |
Aav vectors encoding clarin-1 or gjb2 and uses thereof
|
|
WO2019198084A1
(en)
*
|
2018-04-12 |
2019-10-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-aging compositions and methods of use
|
|
IL278213B2
(en)
|
2018-04-27 |
2026-04-01 |
Rocket Pharmaceuticals Ltd |
A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
|
|
CN112424359A
(zh)
|
2018-05-15 |
2021-02-26 |
沃雅戈治疗公司 |
用于治疗帕金森氏病的组合物和方法
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
WO2019241486A1
(en)
|
2018-06-13 |
2019-12-19 |
Voyager Therapeutics, Inc. |
Engineered 5' untranslated regions (5' utr) for aav production
|
|
JP2021530218A
(ja)
*
|
2018-07-11 |
2021-11-11 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
血液脳関門を超える薬剤の送達のための方法および組成物
|
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
|
EP3830107A2
(en)
|
2018-08-03 |
2021-06-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
US11149256B2
(en)
|
2018-09-26 |
2021-10-19 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
CN113166208B
(zh)
|
2018-10-02 |
2024-11-22 |
沃雅戈治疗公司 |
重新定向aav衣壳的嗜性
|
|
WO2020072849A1
(en)
|
2018-10-04 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
AU2019354793A1
(en)
|
2018-10-05 |
2021-05-13 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding AAV production proteins
|
|
US12467064B2
(en)
|
2018-10-08 |
2025-11-11 |
Allen Institute |
Artificial expression constructs for selectively modulating gene expression in interneurons
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
WO2020081490A1
(en)
|
2018-10-15 |
2020-04-23 |
Voyager Therapeutics, Inc. |
EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM
|
|
WO2020089154A1
(en)
|
2018-10-29 |
2020-05-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Expression vector for cholesterol 24-hydrolase in therapy of amyotrophic lateral sclerosis
|
|
JP7590962B2
(ja)
|
2018-11-05 |
2024-11-27 |
アレン インスティテュート |
皮質興奮性ニューロンにおける遺伝子発現を選択的に調節するための人工発現構築物
|
|
JP2022513618A
(ja)
*
|
2018-11-20 |
2022-02-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
血液脳関門の標的化に有用な組成物および方法
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
CN110437317B
(zh)
*
|
2019-01-30 |
2023-05-02 |
上海科技大学 |
具有变异衣壳蛋白的腺相关病毒及其用途
|
|
AU2020214831B2
(en)
*
|
2019-01-30 |
2025-09-25 |
The Broad Institute, Inc. |
Systems for evolved adeno-associated viruses (AAVs) for targeted delivery
|
|
CN119390787A
(zh)
*
|
2019-01-31 |
2025-02-07 |
俄勒冈健康与科学大学 |
用于aav衣壳的使用转录依赖性定向进化的方法
|
|
CA3142948A1
(en)
|
2019-02-15 |
2020-08-20 |
Allen Institute |
Artificial expression constructs for selectively modulating gene expression in selected neuronal cell populations
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
JP7659271B2
(ja)
*
|
2019-03-28 |
2025-04-09 |
ザ ジェネラル ホスピタル コーポレイション |
導入遺伝子発現のための操作されたアデノ随伴（ａａｖ）ベクター
|
|
CN114450411A
(zh)
|
2019-04-01 |
2022-05-06 |
特纳亚治疗股份有限公司 |
具有工程化衣壳的腺相关病毒
|
|
SG11202111249YA
(en)
|
2019-04-11 |
2021-11-29 |
California Inst Of Techn |
Virus compositions with enhanced specificity in the brain
|
|
GB201905301D0
(en)
|
2019-04-15 |
2019-05-29 |
Ospedale San Raffaele Srl |
Gene therapy
|
|
WO2020223280A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
US20220193261A1
(en)
*
|
2019-04-30 |
2022-06-23 |
The Trustees Of The University Of Pennsylvania |
Compositions useful for treatment of pompe disease
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
EP3972631B1
(en)
|
2019-05-21 |
2024-07-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Expression vector for cholesterol 24-hydrolase in therapy of rett syndrome
|
|
WO2021025995A1
(en)
|
2019-08-02 |
2021-02-11 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
EP4010465A1
(en)
|
2019-08-09 |
2022-06-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
AU2020336332A1
(en)
*
|
2019-08-29 |
2022-03-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Adeno-associated viral vectors for crossing the human blood brain barrier
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
GB201912863D0
(en)
*
|
2019-09-06 |
2019-10-23 |
Babraham Inst |
Novel method
|
|
GB201913974D0
(en)
*
|
2019-09-27 |
2019-11-13 |
King S College London |
Vector
|
|
US20210162002A1
(en)
*
|
2019-10-17 |
2021-06-03 |
The Penn State Research Foundation |
Regenerating functional neurons for treatment of spinal cord injury and als
|
|
CN114787180A
(zh)
*
|
2019-10-17 |
2022-07-22 |
斯特里迪比奥公司 |
用于治疗c型尼曼-匹克病的腺相关病毒载体
|
|
MX2022004353A
(es)
*
|
2019-10-17 |
2022-07-19 |
|
Casete de transferencia de aav.
|
|
WO2021102107A1
(en)
*
|
2019-11-19 |
2021-05-27 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
|
|
CN115023242B
(zh)
*
|
2019-11-22 |
2025-03-14 |
费城儿童医院 |
腺相关病毒载体变体
|
|
CA3167290A1
(en)
|
2020-01-10 |
2021-07-15 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
|
|
FI4103214T3
(fi)
|
2020-02-13 |
2026-07-03 |
Tenaya Therapeutics Inc |
Geeniterapian vektorit sydänsairauden hoitoon
|
|
AU2021259422A1
(en)
|
2020-04-20 |
2022-12-08 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
WO2021216415A1
(en)
*
|
2020-04-20 |
2021-10-28 |
Regents Of The University Of Minnesota |
Compositions and methods for increasing sodium current in cardiac cells
|
|
CN112011571A
(zh)
*
|
2020-04-26 |
2020-12-01 |
辉大(上海)生物科技有限公司 |
一种用于治疗脊髓性肌萎缩的基因治疗药物
|
|
US20230173102A1
(en)
*
|
2020-04-28 |
2023-06-08 |
Genethon |
Use of a Synthetic AAV Capsid for Gene Therapy of Muscle and Central Nervous System Disorders
|
|
AU2021265832A1
(en)
|
2020-04-29 |
2022-11-24 |
The Broad Institute, Inc. |
Machine learning accelerated protein engineering through fitness prediction
|
|
US20230193316A1
(en)
*
|
2020-05-01 |
2023-06-22 |
The Broad Institute, Inc. |
Engineered central nervous system compositions
|
|
US12630842B2
(en)
|
2020-05-13 |
2026-05-19 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
GB202010981D0
(en)
|
2020-07-16 |
2020-09-02 |
Ucl Business Ltd |
Gene therapy for neuromuscular and neuromotor disorders
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
US20230285596A1
(en)
*
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
GB202011871D0
(en)
*
|
2020-07-30 |
2020-09-16 |
Cambridge Entpr Ltd |
Composition and method
|
|
IL300187A
(en)
|
2020-08-05 |
2023-03-01 |
Spacecraft Seven Llc |
Gene therapy CSRP3 (protein 3 rich in cysteine and glycine)
|
|
AU2021321412A1
(en)
|
2020-08-05 |
2023-04-06 |
Spacecraft Seven, Llc |
Adeno-associated viral vector for GLUT1 expression and uses thereof
|
|
EP4192514A1
(en)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
WO2022032226A1
(en)
|
2020-08-07 |
2022-02-10 |
Spacecraft Seven, Llc |
Plakophilin-2 (pkp2) gene therapy using aav vector
|
|
IL300526A
(en)
|
2020-08-17 |
2023-04-01 |
Massachusetts Inst Technology |
Approaches to SHANK3 gene therapy
|
|
JP2023542614A
(ja)
|
2020-08-19 |
2023-10-11 |
サレプタ セラピューティクス， インコーポレイテッド |
レット症候群の治療のためのアデノ随伴ウイルスベクター
|
|
EP4199972A4
(en)
*
|
2020-08-21 |
2025-01-15 |
Capsida, Inc. |
ADENO-ASSOCIATED VIRUS COMPOSITIONS WITH PREFERRED EXPRESSION LEVELS
|
|
CN116096431A
(zh)
*
|
2020-09-10 |
2023-05-09 |
吉尼松公司 |
肽修饰的aav衣壳
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
US20230365963A1
(en)
*
|
2020-09-21 |
2023-11-16 |
Asklepios Biopharmaceutical, Inc. |
Methods for treating neurological disease
|
|
JP2023542950A
(ja)
*
|
2020-09-23 |
2023-10-12 |
シーロス セラピューティクス， インコーポレイテッド |
α－シヌクレインの凝集を阻害するための組成物及び方法
|
|
MX2023003655A
(es)
|
2020-09-29 |
2023-06-22 |
Neuexcell Therapeutics Inc |
Vector neurod1.
|
|
CN112194706B
(zh)
*
|
2020-09-30 |
2022-03-08 |
广州派真生物技术有限公司 |
腺相关病毒突变体及其应用
|
|
US20220154223A1
(en)
|
2020-10-15 |
2022-05-19 |
Hoffmann-La Roche Inc. |
Nucleic acid constructs for simultaneous gene activation
|
|
MX2023005446A
(es)
|
2020-11-11 |
2023-07-18 |
European Molecular Biology Laboratory |
Particulas virales modificadas para terapia genica.
|
|
AR124216A1
(es)
|
2020-12-01 |
2023-03-01 |
Univ Pennsylvania |
Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
|
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
JP7882536B2
(ja)
*
|
2021-03-29 |
2026-06-30 |
南京大学 |
ウイルスベクターに基づくｒｎａ送達システム及びその使用
|
|
WO2022221421A2
(en)
*
|
2021-04-13 |
2022-10-20 |
Capsida, Inc. |
Aav compositions with high brain expression for treating mucopolysaccharidosis ii
|
|
JP2024515626A
(ja)
|
2021-04-16 |
2024-04-10 |
アスクレピオス バイオファーマシューティカル， インコーポレイテッド |
血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
|
|
AU2022262771A1
(en)
|
2021-04-23 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
TW202317768A
(zh)
|
2021-07-08 |
2023-05-01 |
美商特納亞治療股份有限公司 |
用於基因療法的優化表現卡匣
|
|
US20240382617A1
(en)
*
|
2021-09-21 |
2024-11-21 |
Capsida Biotherapeutics, Inc. |
Virus compositions to efficiently target the nervous system and the lungs
|
|
JP2025500347A
(ja)
*
|
2021-10-05 |
2025-01-09 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
操作された心筋組成物
|
|
KR20240095539A
(ko)
|
2021-10-08 |
2024-06-25 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 변이체 및 이의 사용 방법
|
|
JP2024539123A
(ja)
|
2021-10-25 |
2024-10-28 |
ノバルティス アーゲー |
アデノ随伴ウイルス（ａａｖ）送達を改善する方法
|
|
EP4426716A1
(en)
|
2021-11-02 |
2024-09-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
CA3238867A1
(en)
|
2021-11-29 |
2023-06-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
CN114107231B
(zh)
*
|
2021-12-13 |
2023-08-18 |
重庆大学 |
实现全脑突触后神经元胞体标记的重组腺相关病毒及其应用
|
|
US20250346920A1
(en)
|
2022-01-25 |
2025-11-13 |
Voyager Therapeutics, Inc. |
Baculovirus expression system
|
|
CN116554278A
(zh)
*
|
2022-01-30 |
2023-08-08 |
上海玮美基因科技有限责任公司 |
变异型腺相关病毒及其在疾病治疗中的应用
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
EP4482970A1
(en)
|
2022-02-23 |
2025-01-01 |
Massachusetts Institute of Technology |
Methods for upregulating shank3 expression
|
|
CA3253473A1
(en)
*
|
2022-03-03 |
2023-09-07 |
California Institute Of Technology |
COMPOSITIONS AND METHODS FOR CROSSING A BLOOD-BRAIN BARRIER
|
|
JP2025514794A
(ja)
*
|
2022-04-22 |
2025-05-09 |
ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア |
ヒト上衣特異的プロモーターおよびその使用方法
|
|
WO2023240158A2
(en)
*
|
2022-06-07 |
2023-12-14 |
Oregon Health & Science University |
Mutant adeno-associated virus (aav) capsids
|
|
WO2023240236A1
(en)
*
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
WO2024054864A1
(en)
|
2022-09-06 |
2024-03-14 |
Tenaya Therapeutics, Inc. |
Cardioprotective heart disease therapies
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
GB2622629A
(en)
|
2022-09-23 |
2024-03-27 |
Sania Rx Ltd |
Method
|
|
EP4615492A1
(en)
|
2022-11-08 |
2025-09-17 |
Ospedale San Raffaele S.r.l. |
Polynucleotide and vector
|
|
US20260207719A1
(en)
|
2023-02-21 |
2026-07-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of sanfilippo syndrome type iiib
|
|
CN120936709A
(zh)
*
|
2023-03-09 |
2025-11-11 |
新加坡科技研究局 |
经工程化以增强组织转导和特异性的腺相关病毒的新组合物
|
|
JP2026509271A
(ja)
|
2023-03-10 |
2026-03-17 |
ダイノ セラピューティクス，インコーポレーテッド |
カプシドポリペプチドおよびその使用方法
|
|
KR20260016905A
(ko)
|
2023-03-22 |
2026-02-04 |
오스페달레 산 라파엘 에스.알.엘. |
유전자 치료
|
|
JP2026519912A
(ja)
*
|
2023-03-31 |
2026-06-19 |
エクセジェネシス・バイオ・シンガポール・プライベイト・リミテッド |
変異体ａａｖ９カプシドタンパク質及びその使用
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
EP4695396A1
(en)
|
2023-04-10 |
2026-02-18 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024229389A1
(en)
*
|
2023-05-03 |
2024-11-07 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
JP2026515970A
(ja)
*
|
2023-05-04 |
2026-05-19 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖカプシドバリアント及びその使用
|
|
CN121794288A
(zh)
|
2023-05-05 |
2026-04-03 |
麻省理工学院 |
Shank3基因治疗方法
|
|
AU2024271851A1
(en)
|
2023-05-16 |
2025-12-18 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
WO2025007046A1
(en)
|
2023-06-29 |
2025-01-02 |
The Trustees Of The University Of Pennsylvania |
Mutant aav with central nervous system targeting motifs and compositions containing same
|
|
WO2025021839A1
(en)
|
2023-07-25 |
2025-01-30 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat metabolic disorders
|
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
KR20260082361A
(ko)
|
2023-08-31 |
2026-06-04 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 폴리펩타이드 및 이의 사용 방법
|
|
CN117264912A
(zh)
*
|
2023-09-25 |
2023-12-22 |
中国科学院深圳先进技术研究院 |
一种重组腺相关病毒颗粒、重组腺相关病毒载体系统及其应用
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
GB202316264D0
(en)
|
2023-10-24 |
2023-12-06 |
Ospendale San Raffaele S R L |
Gene therapy
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
CN122206466A
(zh)
*
|
2023-11-15 |
2026-06-12 |
建新公司 |
治疗神经变性障碍的方法
|
|
WO2025157848A1
(en)
|
2024-01-23 |
2025-07-31 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the intravenous treatment of sanfilippo syndrome type iiib
|
|
TW202545971A
(zh)
|
2024-02-08 |
2025-12-01 |
美商戴諾治療公司 |
殼體多肽及其使用方法
|
|
WO2025186293A1
(en)
|
2024-03-06 |
2025-09-12 |
Institut National de la Santé et de la Recherche Médicale |
Chmp2b mutants for use for treating infection
|
|
GB202406331D0
(en)
|
2024-05-07 |
2024-06-19 |
Sania Rx Ltd |
Capsid
|
|
WO2026064442A2
(en)
|
2024-09-18 |
2026-03-26 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026096603A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering syntaxin-binding protein-1
|
|
WO2026096600A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering cyclin-dependent kinase-like 5 protein
|
|
WO2026096611A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering cyclin-dependent kinase-like 5 protein
|
|
WO2026096599A1
(en)
|
2024-10-30 |
2026-05-07 |
Neurocrine Biosciences, Inc. |
Compositions and methods for delivering syntaxin-binding protein-1
|
|
WO2026102093A1
(en)
*
|
2024-11-07 |
2026-05-15 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2026122963A1
(en)
|
2024-12-06 |
2026-06-11 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026162810A1
(en)
|
2025-02-03 |
2026-08-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the intravenous treatment of sanfilippo syndrome type iiia
|